Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma

Richard Maziarz, Yanni Hao, Annie Guerin, Genevieve Gauthier, Marjolaine Gauthier-Loiselle, Simu K. Thomas, Lamis Eldjerou

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

This study describes short-term and long-term healthcare resource utilization (HRU) and costs following an allogeneic hematopoietic stem cell transplant (HSCT) in adult patients with diffuse large B-cell lymphoma (DLBCL) in a real-world setting. Among 101 patients with DLBCL receiving an allogeneic HSCT, HRU and direct healthcare costs for up to three years after the allogeneic HSCT are described. HRU and costs were substantial, with the most intensive HRU and highest healthcare costs observed during the first year after HSCT (38 inpatient days; 68 days with office visits and average healthcare costs of $455,741). Although HRU and costs decreased over time, they remained high even in the third year after HSCT (four inpatient days; 27 days with office visits and average healthcare costs of $72,957). Overall, this study showed that the economic burden following an allogeneic HSCT in DLBCL patients is significant.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalLeukemia and Lymphoma
DOIs
StateAccepted/In press - Sep 22 2017

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Hematopoietic Stem Cells
Economics
Transplants
Health Care Costs
Delivery of Health Care
Office Visits
Costs and Cost Analysis
Inpatients

Keywords

  • allogeneic hematopoietic stem cell transplant
  • Diffuse large B-cell lymphoma
  • economic burden
  • healthcare costs
  • healthcare resource utilization

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma. / Maziarz, Richard; Hao, Yanni; Guerin, Annie; Gauthier, Genevieve; Gauthier-Loiselle, Marjolaine; Thomas, Simu K.; Eldjerou, Lamis.

In: Leukemia and Lymphoma, 22.09.2017, p. 1-10.

Research output: Contribution to journalArticle

Maziarz, Richard ; Hao, Yanni ; Guerin, Annie ; Gauthier, Genevieve ; Gauthier-Loiselle, Marjolaine ; Thomas, Simu K. ; Eldjerou, Lamis. / Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma. In: Leukemia and Lymphoma. 2017 ; pp. 1-10.
@article{5a760188c3594f47ab80b076e52fb0cb,
title = "Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma",
abstract = "This study describes short-term and long-term healthcare resource utilization (HRU) and costs following an allogeneic hematopoietic stem cell transplant (HSCT) in adult patients with diffuse large B-cell lymphoma (DLBCL) in a real-world setting. Among 101 patients with DLBCL receiving an allogeneic HSCT, HRU and direct healthcare costs for up to three years after the allogeneic HSCT are described. HRU and costs were substantial, with the most intensive HRU and highest healthcare costs observed during the first year after HSCT (38 inpatient days; 68 days with office visits and average healthcare costs of $455,741). Although HRU and costs decreased over time, they remained high even in the third year after HSCT (four inpatient days; 27 days with office visits and average healthcare costs of $72,957). Overall, this study showed that the economic burden following an allogeneic HSCT in DLBCL patients is significant.",
keywords = "allogeneic hematopoietic stem cell transplant, Diffuse large B-cell lymphoma, economic burden, healthcare costs, healthcare resource utilization",
author = "Richard Maziarz and Yanni Hao and Annie Guerin and Genevieve Gauthier and Marjolaine Gauthier-Loiselle and Thomas, {Simu K.} and Lamis Eldjerou",
year = "2017",
month = "9",
day = "22",
doi = "10.1080/10428194.2017.1375100",
language = "English (US)",
pages = "1--10",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma

AU - Maziarz, Richard

AU - Hao, Yanni

AU - Guerin, Annie

AU - Gauthier, Genevieve

AU - Gauthier-Loiselle, Marjolaine

AU - Thomas, Simu K.

AU - Eldjerou, Lamis

PY - 2017/9/22

Y1 - 2017/9/22

N2 - This study describes short-term and long-term healthcare resource utilization (HRU) and costs following an allogeneic hematopoietic stem cell transplant (HSCT) in adult patients with diffuse large B-cell lymphoma (DLBCL) in a real-world setting. Among 101 patients with DLBCL receiving an allogeneic HSCT, HRU and direct healthcare costs for up to three years after the allogeneic HSCT are described. HRU and costs were substantial, with the most intensive HRU and highest healthcare costs observed during the first year after HSCT (38 inpatient days; 68 days with office visits and average healthcare costs of $455,741). Although HRU and costs decreased over time, they remained high even in the third year after HSCT (four inpatient days; 27 days with office visits and average healthcare costs of $72,957). Overall, this study showed that the economic burden following an allogeneic HSCT in DLBCL patients is significant.

AB - This study describes short-term and long-term healthcare resource utilization (HRU) and costs following an allogeneic hematopoietic stem cell transplant (HSCT) in adult patients with diffuse large B-cell lymphoma (DLBCL) in a real-world setting. Among 101 patients with DLBCL receiving an allogeneic HSCT, HRU and direct healthcare costs for up to three years after the allogeneic HSCT are described. HRU and costs were substantial, with the most intensive HRU and highest healthcare costs observed during the first year after HSCT (38 inpatient days; 68 days with office visits and average healthcare costs of $455,741). Although HRU and costs decreased over time, they remained high even in the third year after HSCT (four inpatient days; 27 days with office visits and average healthcare costs of $72,957). Overall, this study showed that the economic burden following an allogeneic HSCT in DLBCL patients is significant.

KW - allogeneic hematopoietic stem cell transplant

KW - Diffuse large B-cell lymphoma

KW - economic burden

KW - healthcare costs

KW - healthcare resource utilization

UR - http://www.scopus.com/inward/record.url?scp=85029724172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029724172&partnerID=8YFLogxK

U2 - 10.1080/10428194.2017.1375100

DO - 10.1080/10428194.2017.1375100

M3 - Article

C2 - 28933643

AN - SCOPUS:85029724172

SP - 1

EP - 10

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

ER -